SCHEMBL263628

SCHEMBL263628

CCOC(=O)c1c[nH]nc1C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
PDE4D Q08499 1/20 0.50
ALDH1A1 P00352 5/20 0.49
ALOX15 P16050 1/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HSD17B10 Q99714 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
HPGD P15428 1/20 0.43
NUDT1 P36639 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL30271685 0.89 MEN1 (0.43) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL4748492 0.84 TSHR (0.56) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL3376695 0.83 KDM4E (0.51) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL2147241 0.83 KMT2A (0.50) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL161443 0.83 KMT2A (0.50) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL23824155 0.81 KMT2A (0.49) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL3356162 0.81 KMT2A (0.49) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL309808 0.81 ALDH1A1 (0.54) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL416936 0.81 KMT2A (0.49) TSHRKMT2AMEN1PDE4DALDH1A1
SCHEMBL370881 0.81 KMT2A (0.49) TSHRKMT2AMEN1PDE4DALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
EP-4725493-A2 POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF Shenzhen Keye Life Technologies, Co., Ltd. (CN) 2026-04-15 EP disclosed
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO INC (US) 2026-03-12 US disclosed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 US disclosed
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus MERCK SHARP & DOHME LLC 2026-03-03 US disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
EP-4648851-A1 SUBSTITUTED (HETERO)ANILINES AND THEIR USE Astrazeneca AB (SE) 2025-11-19 EP disclosed
US-12459913-B2 Preparation of substituted pyrazoles and their use as anthranilamides precursors ADAMA MAKHTESHIM LTD. (IL) 2025-11-04 US disclosed
US-12428421-B2 Pyrimidinones as factor XIA inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-30 US disclosed
EP-1457490-A1 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity Takeda Chemical Industries, Ltd. (JP) 2004-09-15 EP disclosed
EP-1228067-B1 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-07-14 EP disclosed
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed
EP-1357115-A1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed
EP-1228067-A1 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGYLCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2002-08-07 EP disclosed
WO-2001038325-A1 5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-31 WO disclosed
WO-2000076511-A1 CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-12-21 WO disclosed
WO-2000076514-A1 CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-12-21 WO disclosed
US-4792565-A Pyrazolecarbonylamine derivatives and agricultural and horticultural fungicides containing said compounds MITSUI TOATSU CHEMICALS, INC. (JP) 1988-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof GPR119, ACOX1, ALK TSHR 2334/4885KMT2A 705/4885MEN1 3721/4885
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 TSHR 1670/4885KMT2A 2072/4885MEN1 800/4885
US-12428421-B2 Pyrimidinones as factor XIA inhibitors TFPI, TFPI2, F2 TSHR 2886/4885KMT2A 1129/4885MEN1 869/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD TSHR 2794/4885KMT2A 2305/4885MEN1 1888/4885
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus NHERF1, ZC3HAV1, SARS1 TSHR 1587/4885KMT2A 3932/4885MEN1 630/4885
US-12459913-B2 Preparation of substituted pyrazoles and their use as anthranilamides precursors CYP2F1, PPOX, CYP11B2 TSHR 2521/4885KMT2A 975/4885MEN1 2841/4885
US-20260069602-A1 COMPOUNDS, COMPOSITIONS, AND METHODS SCTR, SSTR1, NPY1R TSHR 89/4885KMT2A 4817/4885MEN1 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.